2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Abstract

In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.